太龍藥業(600222.SH):眾生實業擬將14.37%股份轉讓予泰容產投 控股股東將變更為泰容產投
格隆匯11月29日丨太龍藥業(600222.SH)公佈,2021年11月29日,公司控股股東鄭州眾生實業集團有限公司(“眾生實業”或“轉讓方”)與鄭州泰容產業投資有限公司(“泰容產投”或“受讓方”)簽署了《股份轉讓協議》,泰容產投受讓眾生實業持有的8244.12萬股公司股份,佔公司總股本的14.37%,轉讓價格為每股人民幣9.70元,轉讓價款合計為人民幣7.997億元。
本次交易完成後,公司控股股東將由眾生實業變更為泰容產投,公司實際控制人也將由鞏義市竹林鎮人民政府變更為鄭州高新技術產業開發區管委會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.